title: Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.
abstract: Tissue-based determination of Ki-67, a marker of cellular proliferation, has shown prognostic value in solid tumors and hematological malignancies. We developed and validated an electrochemiluminescence-based method for sensitive measurement of circulating Ki-67 in plasma (cKi-67). This assay demonstrated significantly higher levels of cKi-67 in patients with newly diagnosed acute lymphoblastic leukemia (ALL) (n=27; median, 762; range, 0-4574U/100 microL) than in healthy control subjects (n=114; median, 399; range, 36-2830U/100 microL). Moreover, elevated plasma cKi-67 was associated with significantly shorter survival in ALL patients (P=0.05). These findings suggest that Ki-67 can be detected in circulation and has potential for use as a biomarker for predicting clinical behavior in ALL.
authors.affiliation: Hematology, Quest Diagnostics Nichols Institute, Building A, Hematopathology/Oncology R&D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States. jeanmarie.x.bruey@questdiagnostics.com
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Bruey
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Zeev
authors.initials: Z
authors.lastname: Estrov
authors.forename: Zhong
authors.initials: Z
authors.lastname: Zhang
authors.forename: Wanlong
authors.initials: W
authors.lastname: Ma
authors.forename: Ferras
authors.initials: F
authors.lastname: Albitar
authors.forename: Adam
authors.initials: A
authors.lastname: Abdool
authors.forename: Deborah
authors.initials: D
authors.lastname: Thomas
authors.forename: Chenhsiung
authors.initials: C
authors.lastname: Yeh
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Maher
authors.initials: M
authors.lastname: Albitar
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000592:standards; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood*; D008163:Luminescent Measurements / Q000379:methods / Q000592:standards; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen
references.citation: Scand J Urol Nephrol. 2009;43(1):12-8
references.pmid: 18949633
references.citation: Neoplasma. 2005;52(5):420-4
references.pmid: 16151588
references.citation: Leuk Res. 2003 Oct;27(10):903-8
references.pmid: 12860010
references.citation: J Surg Oncol. 1998 Jan;67(1):33-7
references.pmid: 9457254
references.citation: Blood. 2003 Apr 1;101(7):2507-13
references.pmid: 12446458
references.citation: Cancer Lett. 1997 May 19;115(2):229-34
references.pmid: 9149129
references.citation: J Natl Cancer Inst. 2007 Jul 4;99(13):1053; author reply 1053-4
references.pmid: 17596578
references.citation: Proc Natl Acad Sci U S A. 1985 May;82(10):3262-6
references.pmid: 2860667
references.citation: Oncol Rep. 1999 Sep-Oct;6(5):1117-22
references.pmid: 10425312
references.citation: Cancer Gene Ther. 2009 Jan;16(1):20-32
references.pmid: 18690204
references.citation: J Cell Physiol. 2000 Mar;182(3):311-22
references.pmid: 10653597
references.citation: Cancer Sci. 2008 Aug;99(8):1564-9
references.pmid: 18754867
references.citation: N Engl J Med. 2004 Apr 8;350(15):1535-48
references.pmid: 15071128
references.citation: Blood. 2004 Apr 1;103(7):2799-801
references.pmid: 14576069
references.citation: Exp Cell Res. 2000 Jun 15;257(2):231-7
references.pmid: 10837136
references.citation: J Natl Cancer Inst. 1987 Dec;79(6):1333-40
references.pmid: 3320449
references.citation: Rocz Akad Med Bialymst. 2002;47:262-9
references.pmid: 12533969
references.citation: Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61
references.pmid: 15182827
references.citation: Histopathology. 2007 Oct;51(4):491-8
references.pmid: 17711446
references.citation: J Immunol. 1984 Oct;133(4):1710-5
references.pmid: 6206131
references.citation: Expert Rev Mol Diagn. 2007 Sep;7(5):615-23
references.pmid: 17892367
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7212-20
references.pmid: 16192605
references.citation: Histopathology. 2002 Jan;40(1):2-11
references.pmid: 11903593
references.citation: Breast Cancer Res Treat. 2009 Jul;116(1):53-68
references.pmid: 18592370
references.citation: Br J Haematol. 2003 Dec;123(5):850-7
references.pmid: 14632776
references.citation: Cancer. 2004 Sep 1;101(5):999-1008
references.pmid: 15329909
references.citation: FASEB J. 2003 Mar;17(3):333-40
references.pmid: 12631573
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77
references.pmid: 17508214